Novo Nordisk: Oversold at $49, Needs $50 Reclaim to Stabilize Ahead of Earnings
$Novo-Nordisk A/S(NVO)$
$49.46 (−1.16%): Oversold test of the $49 handle; reclaim of $50–$50.5 needed to steady into earnings
Market Recap (as of Oct 31, 2025):
Novo Nordisk ADR (NVO) closed at $49.46 (−1.16%), trading $48.49–$49.47 on the day. Volume 19.22M vs 15.19M avg (~1.26×), indicating distribution pressure.
Overnight indications show $49.82 (+0.73%). Shares sit near YTD lows (52-wk range $45.05–$112.52).
Technical Indicators Analysis:
RSI(14) ≈ 26 (oversold). MACD is below signal with a negative histogram—down-momentum persists.
Price is below short-term trend gauges (DEMA-9 ≈ $50.07, EMA-9 ≈ $52.06), so bulls need a quick reclaim of $50–$50.5 to avoid a deeper slide.
Base case (1–3 wks): attempt to base above $48.5; bounce path opens if $50.5 is recaptured. Failure to hold the floor risks $47–$46.
Support / Resistance:
Support: $48/$45
Resistance: $52–$53
Valuation and Target Range:
TTM P/E ≈ 12.75, beta ~0.33, forward dividend yield ~3.49%. Street 1-yr target ~ $60. Near-term trading map: hold $48.5–$49 → aim $50–$50.5; a sustained close > $50.5 targets $52–$53 into the Nov 5 earnings window.
Risk Statement:
Drug/pricing headlines, GLP-1 demand updates, FX, and the upcoming earnings call can overwhelm technicals. Technical commentary only—use strict risk controls.
Data Source: Yahoo Finance & TradingView (daily chart, Oct 31, 2025). Prepared by Tiger Morning Brief | For internal use only.
For SG users only, a tool to boost your purchasing power and trading ideas with a Cash Boost Account!
Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with upcoming 0-commission, unlimited trading on SG, HK, and US stocks, as well as ETFs. Find out more here.
Other helpful links:
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
